Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
65.42 USD
0.23%
Market Closed
Updated:
Apr 29, 2024
Gilead Sciences Inc
Cash from Financing Activities
|
Gilead Sciences Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Gilead Sciences Inc's Cash from Financing Activities?
Cash from Financing Activities
-5.1B
USD
-5.1B
USD
Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Cash from Financing Activities amounts to -5.1B USD.
What is Gilead Sciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-7%
-7%
Over the last year, the Cash from Financing Activities growth was 21%.
You don't have any saved screeners yet
